SCHEMBL4254451

SCHEMBL4254451

COc1ccc(/C=C/c2ccc(C(=O)O)cc2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.67
CYP1A1 P04798 2/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP1B1 Q16678 1/20 0.67
ALDH1A1 P00352 2/20 0.66
HPGD P15428 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
KDM4E B2RXH2 1/20 0.66
ALOX15 P16050 1/20 0.66
MAPK1 P28482 1/20 0.66
HSD17B10 Q99714 1/20 0.66
CA1 P00915 2/20 0.66
CA2 P00918 2/20 0.66
CA12 O43570 1/20 0.66
CA4 P22748 1/20 0.66
CA6 P23280 1/20 0.66
CA7 P43166 1/20 0.66
TPMT P51580 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254456 1.00 ABCG2 (0.67) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL5692941 0.90 TSHR (0.70) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL5692937 0.90 TSHR (0.70) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL2449241 0.88 ABCG2 (0.54) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL2449239 0.88 ABCG2 (0.54) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL5692902 0.87 CXCL12 (0.79) ABCG2MEN1KMT2ACYP1A2ALDH1A1
SCHEMBL5692905 0.87 CXCL12 (0.79) ABCG2MEN1KMT2ACYP1A2ALDH1A1
SCHEMBL4265340 0.85 MAPT (0.74) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL4265337 0.85 MAPT (0.74) ABCG2CYP1A1MEN1KMT2ACYP1A2
SCHEMBL5693342 0.85 PKM (0.61) MEN1KMT2ACYP1A2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
EP-0905164-B1 Liquid crystalline polyester compositions and their uses NIPPON MITSUBISHI OIL CORP (JP) 2006-05-03 EP disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed
EP-0905164-A2 Liquid crystalline polyesters, their composition, and their uses NIPPON OIL CO., LTD. (JP) 1999-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 ABCG2 1613/4885CYP1A1 1550/4885MEN1 3991/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 ABCG2 1613/4885CYP1A1 1550/4885MEN1 3991/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 ABCG2 1613/4885CYP1A1 1550/4885MEN1 3991/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 ABCG2 1613/4885CYP1A1 1550/4885MEN1 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.